Stockreport

Aurinia doses first subject in Phase Ia trial of AUR200 for autoimmune diseases [Yahoo! Finance]

Aurinia Pharmaceuticals Inc - Common Shares  (AUPH) 
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.auriniapharma.com
PDF The trial is designed to evaluate the safety, tolerability, pharmacokinetics, and biomarker changes of AUR200 in healthy volunteers. Results from the study are expect [Read more]